The melanoma-antigen family A proteins (MAGE-A), the Preferentially expressed Antigen in Melanoma (PRAME), and the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) are amongst the principal targeted CTAs for cancer vaccines. This evidence concerns the gene PRAME and melanoma.